Efforts to inhibit the release of kynurenine-3-monooxygenase have been shown to reduce 3-hydroxykynurenine levels to alleviate acute kidney injury, prevent multiple organ failure, and ameliorate histological changes in lung tissue that are consistent with ARDS [19,21,38,40]. Here, KMO is linked to acute kidney injury.